Farwell Wildon 4
4 · Dyne Therapeutics, Inc. · Filed Mar 15, 2023
Insider Transaction Report
Form 4
Farwell Wildon
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-03-14$13.33/sh−7,441$99,189→ 92,655 total
Footnotes (2)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021, December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]Includes 74,087 unvested RSUs.